Patents by Inventor Yili Yang
Yili Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115698Abstract: Provided is an anti-IL-5 antibody formulation including an anti-IL-5 antibody, a His buffer, a stabilizer and TWEEN® 80 and having a pH value of 5.70-6.38. The anti-IL-5 antibody formulation of the present invention exhibits better stability than the control under conditions of high temperatures, freezing-thawing, and light, and is more suitable for clinical use.Type: ApplicationFiled: January 30, 2022Publication date: April 11, 2024Inventors: Yili YANG, Xuemin JIANG, Cuihua LIU
-
Publication number: 20240052026Abstract: Related to the field of bioformulations, disclosed is a stable antibody formulation, including an anti-IL-17 antibody, a buffer, a stabilizer, and a surfactant. The stabilizer is methionine or a combination of methionine and a sugar alcohol. The pH value of the antibody formulation is 5.4-6.6. The antibody formulation has improved stability at high temperature and room temperature, can be kept in a liquid form, and is convenient to use.Type: ApplicationFiled: December 21, 2021Publication date: February 15, 2024Inventors: Yili YANG, Xiaoping LUO, Qingrui LI, Zixuan KOU, Yong WU, Cuihua LIU
-
Patent number: 11192954Abstract: The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies.Type: GrantFiled: August 10, 2018Date of Patent: December 7, 2021Assignee: Bio-Thera Solutions, Ltd.Inventors: Weijia Tang, Xiaoyang Huang, Jin-Chen Yu, Ziqiang Ou, Xian Peng, Yili Yang, Shengfeng Li, Chao Qin
-
Patent number: 10400104Abstract: A curable silicone rubber composition is described for an LED enclosure or packaging. A process for preparing the same and the use thereof are also described. Particularly, the compositions can include at least one tackifier component D, which includes: a) a alkenyl or hydrosilyl group including an isocyanurate compound E, and b) an adhesion-imparting ingredient having at least two functional groups selected from the group consisting of alkenyl, epoxy, alkoxy and hydrosilyl groups, which includes of polysiloxane F and optional coupling agents G.Type: GrantFiled: November 20, 2014Date of Patent: September 3, 2019Assignee: ELKEM SILICONES SHANGHAI CO., LTDInventors: Liya Jia, Shifang Zhao, Yili Yang
-
Patent number: 10206920Abstract: The invention provides a pharmaceutical composition and a method for treating cancer, and the composition comprises a proteasome inhibitor and a nuclear export inhibitor. The composition has synergistic effects on treating cancers, particularly a solid tumor cancer. Specifically, the proteasome inhibitor bortezomib and CRM1 inhibitor KPT330 induce apoptosis and cell cycle arrest in sensitive cells, such as HCT116 and RKO cells. Bortezomib induces the nuclear export of p53, whereas it could be effectively blocked by KPT330. CRM1 inhibitor KPT330 synergistically sensitizes CRC cells to bortezomib treatment in vitro and in vivo, through inhibiting nuclear export and restoring functions of p53. The invention also provides use of proteasome inhibitor in a solid tumor cancer. The invention provides a rationale for the use of proteasome inhibitor together with nuclear export blocker in the treatment of cancers, such as colorectal cancer.Type: GrantFiled: November 14, 2017Date of Patent: February 19, 2019Assignee: SUZHOU INSTITUTE OF SYSTEMS MEDICINEInventors: Yili Yang, Long Cui, Tingyu Wu
-
Publication number: 20190048095Abstract: The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies.Type: ApplicationFiled: August 10, 2018Publication date: February 14, 2019Applicant: BIO-THERA SOLUTIONS, LTD.Inventors: Weijia TANG, Xiaoyang HUANG, Jin-Chen YU, Ziqiang OU, Xian PENG, Yili YANG, Shengfeng LI, Chao QIN
-
Publication number: 20180133214Abstract: The invention provides a pharmaceutical composition and a method for treating cancer, and the composition comprises a proteasome inhibitor and a nuclear export inhibitor. The composition has synergistic effects on treating cancers, particularly a solid tumor cancer. Specifically, the proteasome inhibitor bortezomib and CRM1 inhibitor KPT330 induce apoptosis and cell cycle arrest in sensitive cells, such as HCT116 and RKO cells. Bortezomib induces the nuclear export of p53, whereas it could be effectively blocked by KPT330. CRM1 inhibitor KPT330 synergistically sensitizes CRC cells to bortezomib treatment in vitro and in vivo, through inhibiting nuclear export and restoring functions of p53. The invention also provides use of proteasome inhibitor in a solid tumor cancer. The invention provides a rationale for the use of proteasome inhibitor together with nuclear export blocker in the treatment of cancers, such as colorectal cancer.Type: ApplicationFiled: November 14, 2017Publication date: May 17, 2018Inventors: Yili YANG, Long CUI, Tingyu WU
-
Publication number: 20160333182Abstract: A curable silicone rubber composition is described for an LED enclosure or packaging. A process for preparing the same and the use thereof are also described. Particularly, the compositions can include at least one tackifier component D, which includes: a) a alkenyl or hydrosilyl group including an isocyanurate compound E, and b) an adhesion-imparting ingredient having at least two functional groups selected from the group consisting of alkenyl, epoxy, alkoxy and hydrosilyl groups, which includes of polysiloxane F and optional coupling agents G.Type: ApplicationFiled: November 20, 2014Publication date: November 17, 2016Inventors: Liya JIA, Shifang ZHAO, Yili YANG
-
Patent number: 8877765Abstract: The present invention features pyrimido-dione-quinoline compounds having improved solubility, pharmaceutical compositions of substituted pyrimido-dione-quinoline compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more pyrimido-dione-quinoline compounds of the invention.Type: GrantFiled: June 13, 2007Date of Patent: November 4, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Allan M. Weissman, Yili Yang
-
Publication number: 20120289569Abstract: The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.Type: ApplicationFiled: July 12, 2012Publication date: November 15, 2012Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Allan M. Weissman, Yili Yang, Jane P. Jensen
-
Patent number: 8242160Abstract: The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.Type: GrantFiled: July 23, 2010Date of Patent: August 14, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Allan M. Weissman, Yili Yang, Jane P. Jensen
-
Publication number: 20100305180Abstract: The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.Type: ApplicationFiled: July 23, 2010Publication date: December 2, 2010Inventors: Allan M. Weissman, Yili Yang, Jane P. Jensen
-
Publication number: 20100056549Abstract: The present invention features pyrimido-dione-quinoline compounds having improved solubility, pharmaceutical compositions of substituted pyrimido-dione-quinoline compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more pyrimido-dione-quinoline compounds of the invention.Type: ApplicationFiled: June 13, 2007Publication date: March 4, 2010Applicant: Government of the US, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Allan Weissman, Yili Yang
-
Publication number: 20100048593Abstract: The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.Type: ApplicationFiled: February 23, 2009Publication date: February 25, 2010Applicants: Government of the US, as represented by the Secretary, Department of Health & Human Services, BioVeris CorporationInventors: Allan M. Weissman, Karen H. Vousden, Jane P. Jensen, Yili Yang, Shengyun Fang, Douglas Woods, John H. Kenten, Ilia Davydov, Yassamin J. Safiran, Pankaj Oberoi
-
Patent number: 7498336Abstract: The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.Type: GrantFiled: February 12, 2004Date of Patent: March 3, 2009Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, BioVeris CorporationInventors: Allan M. Weissman, Karen H. Vousden, Jane P. Jensen, Yili Yang, Shengyun Fang, Douglas Woods, John H. Kenten, Ilia Davydov, Yassamin J. Safiran, Pankaj Oberoi
-
Publication number: 20080306130Abstract: The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention.Type: ApplicationFiled: May 19, 2008Publication date: December 11, 2008Applicant: Government of the US, as represented by the Secretary, Department of Health and Human ServicesInventors: Allan M. Weissman, Yili Yang, Jane P. Jensen
-
Publication number: 20060211718Abstract: The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.Type: ApplicationFiled: February 12, 2004Publication date: September 21, 2006Applicants: GOVERNMENT OF THE US, AS REPRESENTED BY THE SEC- RETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, BioVERIS CORPORATIONInventors: Allan Weissman, Karen Vousden, Jane Jensen, Yili Yang, Shengyun Fang, Douglas Woods, John Kenten, Ilia Davydov, Yassamin Safiran, Pankaj Oberoi